{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T09:33:39Z","timestamp":1774690419940,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s15010-017-1105-1","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T16:09:04Z","timestamp":1517414944000},"page":"409-418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0231-7218","authenticated-orcid":false,"given":"Bettina M.","family":"Knoll","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Seiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,31]]},"reference":[{"key":"1105_CR1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561\u20136.","journal-title":"Nat Med"},{"key":"1105_CR2","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054\u201361.","journal-title":"Leukemia"},{"key":"1105_CR3","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.2165\/11207580-000000000-00000","volume":"71","author":"PL McCormack","year":"2011","unstructured":"McCormack PL, Keam SJ. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs. 2011;71:1771\u201395.","journal-title":"Drugs"},{"key":"1105_CR4","first-page":"107","volume":"28","author":"YY Syed","year":"2014","unstructured":"Syed YY, McCormack PL, Plosker GL. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Bio Drugs. 2014;28:107\u201320.","journal-title":"Bio Drugs"},{"key":"1105_CR5","first-page":"468","volume":"10","author":"E Jabbour","year":"2007","unstructured":"Jabbour E, Cortes J, Giles F, O\u2019Brien S, Kantarijan H. Drug evaluation: nilotinib\u2014a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. IDrugs. 2007;10:468\u201379.","journal-title":"IDrugs"},{"key":"1105_CR6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s40265-014-0216-6","volume":"74","author":"SM Hoy","year":"2014","unstructured":"Hoy SM. Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs. 2014;74:793\u2013806.","journal-title":"Drugs"},{"key":"1105_CR7","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1002\/ijc.25233","volume":"127","author":"J Salih","year":"2010","unstructured":"Salih J, Hilpert J, Placke T, Gr\u00fcnebach F, Steinle A, Salih HR. Krusch M The BCR\/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer. 2010;127:2119\u201328.","journal-title":"Int J Cancer"},{"key":"1105_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1042\/BJ20141165","volume":"465","author":"J Ozanne","year":"2015","unstructured":"Ozanne J, Prescott AR. Clark K Theclinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-indcible kinases. Biochem J. 2015;465:271\u20139.","journal-title":"Biochem J"},{"key":"1105_CR9","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","volume":"105","author":"R Seggewiss","year":"2005","unstructured":"Seggewiss R, Lor\u00e9 K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood. 2005;105:2473\u20139.","journal-title":"Blood"},{"key":"1105_CR10","first-page":"1133","volume":"31","author":"J Chen","year":"2007","unstructured":"Chen J, Schmitt A, Giannopoulos K, et al. Imatinib impairs the proliferation and function of CD4\u00a0+\u00a0CD25\u00a0+\u00a0regulatory T cells in a dose-dependent manner. Int J Oncol. 2007;31:1133\u20139.","journal-title":"Int J Oncol"},{"key":"1105_CR11","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1111\/j.1582-4934.2008.00234.x","volume":"12","author":"J Chen","year":"2008","unstructured":"Chen J, Schmitt A, Chen B, et al. Nilotinib hampers the proliferation and function of CD8\u00a0+\u00a0T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med. 2008;12:2107\u201318.","journal-title":"J Cell Mol Med"},{"key":"1105_CR12","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.exphem.2008.05.002","volume":"36","author":"F Fei","year":"2008","unstructured":"Fei F, Yu Y, Schmitt A, et al. Dasatinib exerts an immunosuppressive effect on CD8\u00a0+\u00a0T cells specific for viral and leukemia antigens. Exp Hematol. 2008;36:1297\u2013308.","journal-title":"Exp Hematol"},{"key":"1105_CR13","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1158\/1078-0432.CCR-07-4393","volume":"14","author":"R Weichsel","year":"2008","unstructured":"Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res. 2008;14:2484\u201391.","journal-title":"Clin Cancer Res"},{"key":"1105_CR14","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3109\/10428194.2011.647017","volume":"53","author":"Y Hayashi","year":"2012","unstructured":"Hayashi Y, Nakamae H, Katayama T, et al. Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib. Leuk Lymphoma. 2012;53:1084\u20139.","journal-title":"Leuk Lymphoma"},{"key":"1105_CR15","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, et al. IRIS Investigators Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994\u20131004.","journal-title":"N Engl J Med"},{"key":"1105_CR16","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139.","journal-title":"N Engl J Med"},{"key":"1105_CR17","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044\u201354.","journal-title":"Leukemia"},{"key":"1105_CR18","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/ajh.23788","volume":"89","author":"C Gambacorti-Passerini","year":"2014","unstructured":"Gambacorti-Passerini C, Cortes JE, Lipton JH, et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol. 2014;89:947\u201353.","journal-title":"Am J Hematol"},{"key":"1105_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/bjh.13108","volume":"168","author":"TH Br\u00fcmmendorf","year":"2015","unstructured":"Br\u00fcmmendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvilli\u00e9 L, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015;168:69\u201381.","journal-title":"Br J Haematol"},{"key":"1105_CR20","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783\u201396.","journal-title":"N Engl J Med"},{"key":"1105_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.2169\/internalmedicine.44.114","volume":"44","author":"M Takashima","year":"2005","unstructured":"Takashima M, Igaki N, Matsuda T, Ohyama M, Kanda S, Tamada F, Goto T. Malignant gastrointestinal stromal tumor of the small intestine complicated with pulmonary tuberculosis during treatment with imatinib mesylate. Intern Med. 2005;44:114\u20139.","journal-title":"Intern Med"},{"key":"1105_CR22","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1001\/archinternmed.2008.581","volume":"169","author":"L Senn","year":"2009","unstructured":"Senn L, Kovacsovics T, Tarr PE, Meylan P. Peritoneal tuberculosis after imatinib therapy. Arch Intern Med. 2009;169:312\u20133.","journal-title":"Arch Intern Med"},{"key":"1105_CR23","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1183\/09031936.00025408","volume":"33","author":"JM Daniels","year":"2009","unstructured":"Daniels JM, Vonk-Noordegraaf A, Janssen JJ, Postmus PE, van Altena R. Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia. Eur Respir J. 2009;33:670\u20132.","journal-title":"Eur Respir J"},{"key":"1105_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/14639230500236818","volume":"47","author":"K Ikeda","year":"2006","unstructured":"Ikeda K, Shiga Y, Takahashi A, Kai T, Kimura H, Takeyama K, et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma. 2006;47:155\u20137.","journal-title":"Leuk Lymphoma"},{"key":"1105_CR25","first-page":"e86","volume":"49","author":"TJ Thia","year":"2008","unstructured":"Thia TJ, Tan HH, Chuah TH, Chow WC, Lui HF. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. Singapore Med J. 2008;49:e86\u20139.","journal-title":"Singapore Med J"},{"key":"1105_CR26","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s12072-008-9099-5","volume":"2","author":"S Lakhani","year":"2008","unstructured":"Lakhani S, Davidson L, Priebat DA, Sherker AH. Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy. Hepatol Int. 2008;2:498\u20139.","journal-title":"Hepatol Int."},{"key":"1105_CR27","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.transproceed.2010.02.038","volume":"42","author":"SG Kim","year":"2010","unstructured":"Kim SG, Chun JM, Jin R, Kim JY, Won DI, Hwang YJ. Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports. Transpl Proc. 2010;42:843\u20135.","journal-title":"Transpl Proc"},{"key":"1105_CR28","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.3748\/wjg.v19.i8.1318","volume":"19","author":"GM Lai","year":"2013","unstructured":"Lai GM, Yan SL, Chang CS, Tsai CY. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. World J Gastroenterol. 2013;19:1318\u201321.","journal-title":"World J Gastroenterol"},{"key":"1105_CR29","first-page":"3629","volume":"34","author":"EJ Walker","year":"2014","unstructured":"Walker EJ, Simko JP, Ko AH. Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor. Anticancer Res. 2014;34:3629\u201334.","journal-title":"Anticancer Res"},{"key":"1105_CR30","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12185-015-1788-y","volume":"102","author":"T Ando","year":"2015","unstructured":"Ando T, Kojima K, Isoda H, Eguchi Y, Honda T, Ishigami M, Kimura S. Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia. Int J Hematol. 2015;102:379\u201382.","journal-title":"Int J Hematol"},{"key":"1105_CR31","unstructured":"http:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/hc-sc\/2016\/58222a-eng.php . Accessed 07 July 2017"},{"key":"1105_CR32","first-page":"976","volume":"9","author":"GN Mattiuzzi","year":"2003","unstructured":"Mattiuzzi GN, Cortes JE, Talpaz M, et al. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res. 2003;9:976\u201380.","journal-title":"Clin Cancer Res"},{"key":"1105_CR33","doi-asserted-by":"publisher","first-page":"e2011021","DOI":"10.4084\/mjhid.2011.021","volume":"3","author":"M Breccia","year":"2011","unstructured":"Breccia M, Girmenia C, Latagliata R, et al. Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase. Mediterr J Hematol Infect Dis. 2011;3:e2011021.","journal-title":"Mediterr J Hematol Infect Dis."},{"key":"1105_CR34","doi-asserted-by":"publisher","first-page":"4243","DOI":"10.1182\/blood-2003-07-2436","volume":"102","author":"MW Bekkenk","year":"2003","unstructured":"Bekkenk MW, Vermeer MH, Meijer CJ, Jansen PM, Middeldorp JM, Stevens SJ, Willemze R. EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate. Blood. 2003;102:4243.","journal-title":"Blood"},{"key":"1105_CR35","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/sj.leu.2404758","volume":"21","author":"T Leguay","year":"2007","unstructured":"Leguay T, Foucaud C, Parrens M, Fitoussi O, Bouabdallah K, Belaud-Rotureau MA, Tabrizi R, Marit G, Pigneux A, Milpied N. EBV-positive lymphoproliferative disease with medullary, splenic and hepatic infiltration after imatinib mesylate therapy for chronic myeloid leukemia. Leukemia. 2007;21:2208\u201310.","journal-title":"Leukemia"},{"key":"1105_CR36","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jaapos.2009.09.007","volume":"13","author":"FA Irshad","year":"2009","unstructured":"Irshad FA, Gordon RA. Bartonella henselae neuroretinitis in a 15-year-old girl with chronic myelogenous leukemia. J AAPOS. 2009;13:602\u20134.","journal-title":"J AAPOS."},{"key":"1105_CR37","first-page":"e16","volume":"48","author":"MA Durosinmi","year":"2007","unstructured":"Durosinmi MA, Ogbe PO, Salawu L, Oyekunle AA. Herpes zoster complicating imatinib mesylate for gastrointestinal stromal tumour. Singapore Med J. 2007;48:e16\u20138.","journal-title":"Singapore Med J"},{"key":"1105_CR38","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.leukres.2010.05.019","volume":"34","author":"N Anthony","year":"2010","unstructured":"Anthony N, Shanks J, Terebelo H. Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate. Leuk Res. 2010;34:1250\u20131.","journal-title":"Leuk Res"},{"key":"1105_CR39","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/13693780701558969","volume":"46","author":"M Speletas","year":"2008","unstructured":"Speletas M, Vyzantiadis TA, Kalala F, Plastiras D, Kokoviadou K, Antoniadis A, Korantzis I. Pneumonia caused by Candida krusei and Candida glabrata in a patient with chronic myeloid leukemia receiving imatinib mesylate treatment. Med Mycol. 2008;46:259\u201363.","journal-title":"Med Mycol"},{"key":"1105_CR40","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/bmt.2012.246","volume":"48","author":"M W\u00f6lfl","year":"2013","unstructured":"W\u00f6lfl M, Langhammer F, Wiegering V, Eyrich M, Schlegel PG. Dasatinib medication causing profound immunosuppression in a patient after haploidentical SCT: functional assays from whole blood as diagnostic clues. Bone Marrow Transpl. 2013;48:875\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"1105_CR41","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.tranon.2015.12.004","volume":"9","author":"F Davalos","year":"2016","unstructured":"Davalos F, Chaucer B, Zafar W, Salman S, Nfonoyim J. Dasatinib-induced CMV hepatitis in an immunocompetent patient: a rare complication of a common drug. Transl Oncol. 2016;9:248\u201350.","journal-title":"Transl Oncol."},{"key":"1105_CR42","first-page":"282","volume":"52","author":"Y Sunami","year":"2011","unstructured":"Sunami Y, Sato E, Ichikawa K, Yasuda H, Komatsu N. Hemorrhagic colitis caused by dasatinib following cytomegalovirus enterocolitis in a patient with chronic myelogenous leukemia in the second chronic phase. Rinsho Ketsueki. 2011;52:282\u20136.","journal-title":"Rinsho Ketsueki."},{"key":"1105_CR43","first-page":"77","volume":"26","author":"MA Yassin","year":"2015","unstructured":"Yassin MA, Nashwan AJ, Soliman AT, Yousif A, Moustafa A, AlBattah A, et al. Cytomegalovirus-induced hemorrhagic colitis in a patient with chronic myeloid leukemia (chronic phase) on dasatinib as an upfront therapy. Clin Med Insights Case Rep. 2015;26:77\u201381.","journal-title":"Clin Med Insights Case Rep."},{"key":"1105_CR44","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/j.1365-2362.2009.02206.x","volume":"39","author":"C Sillaber","year":"2009","unstructured":"Sillaber C, Herrmann H, Bennett K, Rix U, Baumgartner C, B\u00f6hm A, et al. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140\u00a0mg daily. Eur J Clin Invest. 2009;39:1098\u2013109.","journal-title":"Eur J Clin Invest"},{"key":"1105_CR45","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ijid.2014.04.030","volume":"25","author":"H Chang","year":"2014","unstructured":"Chang H, Hung YS, Chou WC. Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment. Int J Infect Dis. 2014;25:165\u20137.","journal-title":"Int J Infect Dis."},{"key":"1105_CR46","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119:1123\u20139.","journal-title":"Blood"},{"key":"1105_CR47","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333\u201340.","journal-title":"J Clin Oncol"},{"key":"1105_CR48","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ajh.21615","volume":"85","author":"MB Lilly","year":"2010","unstructured":"Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, et al. Dasatinib 140\u00a0mg once daily versus 70\u00a0mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study. Am J Hematol. 2010;85:164\u201370.","journal-title":"Am J Hematol"},{"key":"1105_CR49","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.3109\/10428194.2012.656626","volume":"53","author":"GH Rodriguez","year":"2012","unstructured":"Rodriguez GH, Ahmed SI, Al Akhrass F, Rallapalli V, Safdar A. Characteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications. Leuk Lymphoma. 2012;53:1530\u20135.","journal-title":"Leuk Lymphoma"},{"key":"1105_CR50","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/cid\/cix325","volume":"65","author":"DP Prestes","year":"2017","unstructured":"Prestes DP, Arbona E, Nevett-Fernandez A, Woolley AE, Ho VT, Koo S, et al. Dasatinib use and risk of cytomegalovirus reactivation after allogeneic hematopoietic-cell transplantation. Clin Infect Dis. 2017;65:510\u20133.","journal-title":"Clin Infect Dis"},{"key":"1105_CR51","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","volume":"16","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16:1547\u201355.","journal-title":"Lancet Oncol."}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s15010-017-1105-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-017-1105-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-017-1105-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T21:39:16Z","timestamp":1719783556000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s15010-017-1105-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,31]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["1105"],"URL":"https:\/\/doi.org\/10.1007\/s15010-017-1105-1","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,31]]},"assertion":[{"value":"7 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}